Olema Pharmaceuticals, Inc. OLMA
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 7.31% | 27.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.85% | 15.78% | |||
| Operating Income | -15.85% | -15.78% | |||
| Income Before Tax | -19.05% | -15.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.05% | -15.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.05% | -15.26% | |||
| EBIT | -15.85% | -15.78% | |||
| EBITDA | -15.92% | -15.97% | |||
| EPS Basic | -17.18% | -2.38% | |||
| Normalized Basic EPS | -17.16% | -2.38% | |||
| EPS Diluted | -17.18% | -2.38% | |||
| Normalized Diluted EPS | -17.16% | -2.38% | |||
| Average Basic Shares Outstanding | 1.61% | 12.57% | |||
| Average Diluted Shares Outstanding | 1.61% | 12.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||